TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31136460
Drug: Posturing alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posturing alone (Treatment B)
Study: 25019968
Drug: Endoscopic flushing
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic flushing with pronase (50 mL of water, pronase, sodium bicarbonate, and DMPS)
Study: 17765048
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic regimens (7 days or less)
Study: 17765048
Drug: Extended-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-course antibiotic regimens (>7 days)
Study: 12351249
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.83 micro g. kg(‐1). min(‐1) (Group R)
Study: 12351249
Drug: Fentanyl bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl bolus, small dose, at 12 micro g/kg (Group FLD)
Study: 12351249
Drug: Fentanyl bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl bolus, moderate dose, at 24 micro g/kg (Group FMD)
Study: 9832574
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (40 parts per million)
Study: 8137928
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g orally)
Study: 2733576
Drug: 6% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose solution
Study: 2733576
Drug: 6% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% sucrose solution
Study: 2733576
Drug: 6% fructose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% fructose solution
Study: 786825
Drug: High-dose neurotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose neurotropic vitamins (Neurotrat forte)
Study: 31733182
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg) plus aspirin (75 to 100 mg) once daily
Study: 31733182
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) plus aspirin (75 to 100 mg) once daily
Study: 20329690
Drug: Levonorgestrel regimen
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel regimen (0.75 mg taken twice in 12-hour intervals within 72 hours after unprotected intercourse)
Study: 20329690
Drug: Yuzpe method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe method (two HD contraceptive pills)
Study: 15047681
Drug: Tomato puree
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato puree supplementation (96 g/day for three weeks)
Study: 8392150
Drug: Sumatriptan (SC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (SC, 6 mg; three attacks)
Study: 12975409
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker
Study: 30384381
Drug: Genotype-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided treatment allocation (G‐allele carriers receiving naltrexone)
Study: 30384381
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (random treatment allocation to acamprosate or naltrexone)
Study: 27743738
Drug: Clear Cell
Normalized name: Umbilical Cord Blood Mononuclear Cells Conditioned Medium
DrugBank: Human umbilical cord blood mononuclear cell-conditioned medium (DB15724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear Cell Carcinoma (CC)
Study: 24614165
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who experienced severe adverse drug reactions
Study: 22471125
Drug: Acupuncture-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-medication group (Baihui (GV 20) and Fengchi (GB 20) acupoints)
Study: 22471125
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (Nimodipine)
Study: 22471125
Drug: Acupuncture-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-medication group
Study: 19167590
Drug: Short-term danazol
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term danazol treatment (200 mg/d for 4 weeks)
Study: 19167590
Drug: Long-term danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term danazol treatment (mean dose of 170 mg/d for >2 years)
Study: 15500196
Drug: benidipine hydrochloride
Normalized name: Benidipine hydrochloride
DrugBank: Benidipine (DB09231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine hydrochloride (4 mg/day)
Study: 15500196
Drug: amlodipine (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (5-7.5 mg/day)
Study: 15500196
Drug: benidipine hydrochloride
Normalized name: Benidipine hydrochloride
DrugBank: Benidipine (DB09231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine hydrochloride (4-8 mg/day)
Study: 9056051
Drug: Lazabemide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 100 mg twice daily
Study: 9056051
Drug: Lazabemide 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 350 mg twice daily
Study: 9056051
Drug: Lazabemide (100-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide (100-350 mg)
Study: 9056051
Drug: Lazabemide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide (single and multiple doses)
Study: 9056051
Drug: Lazabemide (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide (multiple dosing)
Study: 3021189
Drug: Aspirin 10
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10 mg
Study: 3021189
Drug: Aspirin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (in vivo)
Study: 22092512
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant overdentures (IODs)
Study: 20528908
Drug: Bortezomib treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib treatment (four cycles, initially as monotherapy, then combined with glucocorticoid from cycle two to four)
Study: 20528908
Drug: Bortezomib treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib treatment with glucocorticoid
Study: 20528908
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment in vitro
Study: 15101020
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.5-3.0)
Study: 27281490
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg for 14 days
Study: 2510530
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g single preoperative dose)
Study: 2510530
Drug: Cefoxitin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (four 2-g doses)
Study: 27873516
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose EC‐MPS with low dose CsA
Study: 27873516
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CsA with low dose EC‐MPS
Study: 25928131
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment (IT)
Study: 23867209
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (7 days preoperative and 10 days postoperative)
Study: 20619394
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without synbiotic therapy
Study: 22089773
Drug: L-Carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine supplementation (1 g/dose, intravenously three times a week after each HD session)
Study: 22089773
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-Carnitine supplementation)
Study: 19933081
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin 40 mg/m(2) intravenously every 28 days
Study: 19933081
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 36 mg/m(2) intravenously days 1, 8, and 15, repeated every 28 days
Study: 9374563
Drug: Acetaminophen 12
Normalized name: acetaminophen 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 12 mg/kg
Study: 7955970
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance during pregnancy (0.05 U kg-1 intravenously)
Study: 7955970
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance after pregnancy (0.05 U kg-1 intravenously)
Study: 3790639
Drug: Naltrexone, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, 300 mg/day
Study: 31206613
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 50 mg/kg IV plus 500 mg oral twice per day for 3 months
Study: 28729158
Drug: Dolutegravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir plus abacavir and lamivudine (single-tablet regimen)
Study: 28729158
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine (three-tablet combination)
Study: 21823280
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding combined vessel pricking therapy (group A)
Study: 21823280
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Sulfasalazine (SASP) (group B)
Study: 16768632
Drug: Extended-release dexmethylphenidate
Normalized name: dexmethylphenidate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day
Study: 11152929
Drug: Tablet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 1-mg folic acid, 1-mg B12, and 25-mg B6
Study: 11152929
Drug: Tablet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 2.5-mg folic acid, 1-mg B12, and 25-mg B6
Study: 8378772
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of chicken type II collagen for 3 months
Study: 27058753
Drug: CA19-9<466 U/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA19-9<466 U/ml
Study: 27058753
Drug: CA19-9>571 U/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA19-9>571 U/ml
Study: 22770683
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment)
Study: 15848983
Drug: Moisturizer containing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer containing urea applied twice daily for 20 days
Study: 15848983
Drug: Patch tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch tests with 0%, 0.5% and 2% NiSO4 in petrolatum
Study: 12877666
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 2.25 microg/kg, s.c., once weekly for 12 weeks
Study: 11895470
Drug: Alcohol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (3 units of ethanol daily for 1 week)
Study: 7907261
Drug: FSH (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH (150 IU twice a week for 2 weeks, then 150 IU FSH and 250 IU hCG twice a week for 4 weeks)
Study: 7907261
Drug: hCG (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG (250 IU twice a week for 6 weeks)
Study: 31093742
Drug: ProTaper retreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProTaper retreatment instruments in combination with gutta‐percha solvent
Study: 25939678
Drug: 4% topical
Normalized name: BPO 4% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% topical glycopyrrolate wipes
Study: 25939678
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical glycopyrrolate wipes
Study: 21705552
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HPP treatment)
Study: 19379093
Drug: Aripiprazole (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (an antipsychotic)
Study: 16817288
Drug: Heparin-coated perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated perfusion system (Group B)
Study: 12771320
Drug: Dietary plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary plant sterol ester (PSE) at a dosage of 2.8 g/d (1.68 g/d phytosterols) for 4 weeks
Study: 10857945
Drug: Repaglinide (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5, 1.0, 2.0 mg in study 1 and 4.0 mg in study 2)
Study: 9118656
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (1.5 g of amino acids/kg/day with 45% branch-chain amino acids)
Study: 9118656
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (1.1 g/kg/day of amino acids with 45% branch-chain amino acids)
Study: 9118656
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (1.5 g of amino acids/kg/day with 23% branch-chain amino acids)
Study: 24809759
Drug: Controller medications
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medications
Study: 18598735
Drug: Sertraline (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100-200 mg/day)
Study: 18598735
Drug: Fluoxetine (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40-80 mg/day)
Study: 10320602
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% (1.0 ml x kg(‐1))
Study: 10320602
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (1.0 ml x kg(‐1))
Study: 7853584
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of 100 mg/m2 neoadjuvant cisplatin before radical cystectomy (arm B)
Study: 1826253
Drug: prazosin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (alpha 1-adrenergic blocker)
Study: 1826253
Drug: atenolol (cardioselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (cardioselective beta-adrenergic blocker)
Study: 1826253
Drug: carteolol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: carteolol (nonselective beta-adrenergic blocker)
Study: 7036354
Drug: Clindamycin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (IV therapy)
Study: 7036354
Drug: Nafcillin/Methicillin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafcillin/Methicillin (IV therapy)
Study: 7036354
Drug: Clindamycin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (oral therapy)
Study: 30794658
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice a day for 7 days)
Study: 30794658
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg twice a day for 7 days)
Study: 26739737
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of physiological saline by an intrauterine catheter
Study: 26739737
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of saline intravaginally
Study: 24503560
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (80 kV, 600 mAs, 50% reduction in contrast medium dose)
Study: 22147447
Drug: Irinotecan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (50 mg/m² weekly), 5-fluorouracil (250 mg/m² for 5 days/week), pelvic radiation (45 Gy/1.8 Gy/fraction for 5 days/week)
Study: 19021619
Drug: Intravesical alkalinized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical alkalinized lidocaine (PSD597) 200 mg lidocaine, alkalinized with 8.4% sodium bicarbonate solution, for 5 consecutive days
Study: 12830369
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ibandronate
Study: 9844703
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution with 37.5 micrograms epinephrine (group C + E)
Study: 9844703
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution without epinephrine (group C)
Study: 8088613
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous bone marrow support (ABMS)
Study: 8088613
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimens with ABMS (cyclophosphamide, cisplatin, thiotepa or cyclophosphamide, carboplatin, mitoxantrone)
Study: 2684006
Drug: Furazolidone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (400 mg)
Study: 4317858
Drug: 780 SE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 780 SE (300 mg)
Study: 22234929
Drug: Guanfacine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (up to 3 mg)
Study: 21947207
Drug: Plant stanols
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanols (8.8 g/day for 10 weeks, followed by 4.5 g at breakfast)
Study: 21947207
Drug: Plant stanols
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanols (4.5 g at breakfast)
Study: 21947207
Drug: Plant stanols
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanols (8.8 g/day for 10 weeks)
Study: 18840641
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 150 mg/month (n = 47)
Study: 221871
Drug: High-dose conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose conjugated estrogens with cyclic progesterone
Study: 25920599
Drug: PDRN injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN injection
Study: 31484712
Drug: Inosine (mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (mild or moderate dosing)
Study: 31484712
Drug: Inosine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (higher dosing)
Study: 27138024
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 400 μg
Study: 26549785
Drug: Glycopyrronium bromide
Normalized name: Glycopyrronium bromide
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium bromide 50 μg
Study: 23362890
Drug: Clonidine 50
Normalized name: cloNIDine 500 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 50 µg (Group C)
Study: 23362890
Drug: Dexmedetomidine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 5 µg (Group D)
Study: 23362890
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% 3 ml + saline 0.5 ml (Group B)
Study: 19528362
Drug: Augmented volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented volume removal therapy
Study: 16732778
Drug: Recorded music
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recorded music therapy
Study: 24092240
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music therapy
Study: 10066844
Drug: Licostinel (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licostinel (0.03 to 3.0 mg/kg)
Study: 7726818
Drug: Methylphenidate (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.7 mg/kg)
Study: 7726818
Drug: Drug placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug placebo
Study: 6102838
Drug: Beta-adrenergic receptor
Normalized name: Beta-adrenergic receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic receptor blocking therapy
Study: 20147617
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein 2b/3a (GP2b/3a) antagonists
Study: 12490017
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of antibiotic (200 mg of ofloxacin) during anesthetic induction
Study: 12490017
Drug: Treatment doses
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment doses of antibiotic (400 mg of ofloxacin per day) until the nephrostomy catheter was removed
Study: 12490017
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single-dose vs short-course)
Study: 6256422
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) treatment in vivo
Study: 6256422
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MP and histamine treatments
Study: 29132988
Drug: PnuBioVax (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PnuBioVax (50, 200, 500 µg)
Study: 29132988
Drug: PnuBioVax (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PnuBioVax (200 µg and 500 µg)
Study: 24723075
Drug: Low-dose statin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statin (LDS)
Study: 24723075
Drug: FA +
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA + Low-dose statin (LDS)
Study: 24723075
Drug: Moderate-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose statin (MDS)